Blinatumomab Consolidation in Real World

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT07117136
Status
Recruiting
Apply to this trial

Conditions

  • B-Cell Acute Lymphoblastic Leukaemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.

Key Dates

Start date
Aug 28, 2025
Status verified
Nov 2025
Primary completion
May 14, 2029
Completion
May 14, 2029

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Patients who received Blinatumomab Therapy
  • Arm: Patients who did not receive Blinatumomab Therapy

Primary Outcome Measure

Percentage of participants with complete remission [ Time Frame: 5 years or e.g., 1 year after closure of study ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Medical College of WisconsinMilwaukeeWisconsin53226
Blong Research Regulatory Specialist, Sr.
[email protected]
4148056330

Find similar trials in Milwaukee, WI

By research site
Medical College of Wisconsin· Milwaukee, WI

Related Studies